Advances therapeutics & companies from discovery to the clinic to commercialization. Recognized on 2018 PharmaVOICE 100 list of the most transformational, influential, & inspirational leaders in the global life sciences industry.

>20 Years in Cell & Gene Therapy, Immunology, Biologics, Therapeutics:

• Immunomodulation of T cells, macrophages, cytokines

• Cell therapy, miRNA, mRNA, allogeneic, small molecules, engineered tissues, exosomes (nature's LNP), epigenetic modifications, AAV

• Immune evasion

Therapeutic Areas:

• Autoimmune, immunology, inflammation, ophthalmology, cardiovascular, vascular dysfunction, nephrology, pulmonology, liver, cancer, fibrosis, orthopedics, urology

Translational and Scientific Leadership for Therapeutics:

• Builds strong, differentiated products, platforms & pipelines

• Optimizes fit-for-purpose therapeutics for scientific, clinical & commercial success

• Translates from discovery to Phase 3 trials

• Creates regulatory & payer strategies & datasets

Strategic Business & Operational Leader:

• Establishes a unified scientific, clinical, regulatory & commercial vision

• Maximizes value of technology platforms

• Sets strategy & operationalizes to achieve milestones

• 19 years in board-facing roles

• Serves on strategic & scientific advisory boards

Notable Accomplishments:

• Co-founded Humacyte, a pioneering regenerative medicine therapeutics company (NASDAQ: HUMA). Advanced bioengineered blood vessel platform from discovery to Phase 3 trials, with a path to reimbursement and a path to BLA. Strong pipeline, strategic & commercial partnerships.

• As CSO of Cell Care, and consulting CSO to VC-backed stealth companies: defines scientific vision, leads discovery & translation, builds high-functioning R&D organizations, defines clear strategy to guide priorities, externally communicates scientific value, partner to CEO on corporate strategy & fundraising.

• Co-authored first RMAT designation ever granted by FDA (like Breakthrough), INDs.

• Negotiated value-based reimbursement path with CMS to replace traditional fee-for-service.

• Inventor on 36 issued patents, author of 21 publications, invited speaker at conferences.

• Represented Humacyte in high profile interviews: The Economist, BBC Radio, WebMD, etc.

Views Leadership as a Team Sport:

• Aligns Boards, C-Suite, teams & stakeholders

• Inspires others to achieve shared goals

• Values strengths of colleagues and their leadership to achieve common goals

• Develops others

• Culture-focused